The case that Ozempic (NVO) and other GLP-1 medications could help people with substance use disorders is getting stronger.

The drugmaker's financial results are also impressive, spearheaded by tirzepatide, a therapy for diabetes and obesity that is ...

Hunsaker finds an improvement in the “volume and variety” of funding from the UKIB and others since his original report into ...

My grandpa really loves golf,” Staunton senior Lilly Bandy said. “He’s always played, so I decided to try it out. I had never ...

Eli Lilly has thrown its weight behind a cause beyond the traditional remit of pharma companies. | Eli Lilly has thrown its ...

Artificial intelligence can revolutionize drug discovery by expediting development, reducing costs, and improving treatment ...

Lilly has been solidly investing in research and development (R&D) throughout 2024. In April, the company announced the ...

Britain will study whether the use of Eli Lilly’s weight loss drug can get people back into work and help tackle the high ...

Drugs such as Novo Nordisk’s Ozempic can cut drug and alcohol abuse by up to 50%, a study found, adding to mounting evidence ...

Unfortunately, many of our elected leaders today undervalue the role of patents to progress the science of drug discovery and ...

The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...

Gilead Sciences (NASDAQ:GILD) and Amgen (NASDAQ:AMGN) with outperform ratings. The investment firm said its bullish ratings on Gilead and Amgen were based on upside expectations for key assets to ...